Prognostic value of minimal residual disease detected by EuroFlow next-generation flow cytometry and next-generation sequencing in patients with multiple myeloma achieving complete response and receiving lenalidomide maintenance after autotransplant: a prospective comparison study
2025; Ferrata Storti Foundation; Linguagem: Inglês
10.3324/haematol.2025.287411
ISSN1592-8721
AutoresTakeshi Yoroidaka, Hiroyuki Takamatsu, Ryota Urushihara, Mitsuhiro Itagaki, Satoshi Yoshihara, Kota Sato, Naoki Takezako, Shuji Ozaki, Kazuhito Suzuki, Kentaro Kohno, Tsuyoshi Muta, Morio Matsumoto, Yasushi Terasaki, Takeshi Yamashita, Shin‐ichi Fuchida, Jun Sakamoto, Tadao Ishida, Kenshi Suzuki, Hirokazu Murakami, Brian G.M. Durie, Kazuyuki Shimizu,
Tópico(s)Cancer Treatment and Pharmacology
Referência(s)